US › Healthcare

Dr. Reddy’s Laboratories Ltd ADR (RDY)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$12.10+0.25%
Last close · 2026-08-04

Latest quarter · ended 2026-06-30

Revenue
$81.18B
Revenue YoY
-5.0%
Net profit
$4.46B
Profit YoY
-68.5%
EPS
$0.06
EPS estimate
$0.17
Net margin
5.5%

EPS came in at 0.06 against a street estimate of 0.17 — a miss of 64.7%.

Key statistics

Market cap
$9.87B
P/E
28.9
Forward P/E
25.8
P/B
2.46
Book value
$0.80
EPS (TTM)
$0.41
Dividend yield
0.70%
52-week high
$15.51
52-week low
$11.28
50-day MA
$13.30
200-day MA
$13.69
Beta
0.26

Analyst view

Analysts rate Dr. Reddy’s Laboratories Ltd ADR a buy (2 buy, 1 hold, 1 sell out of 4) with an average price target of $13.52.

Shareholding

Institutions
15.51%

Largest institutional holders

FundStake
Robeco Institutional Asset Management BV2.16%
BlackRock Inc1.39%
Royal Bank of Canada1.20%
Morgan Stanley - Brokerage Accounts1.12%
Aikya Investment Management Ltd0.96%
Renaissance Technologies Corp0.94%
Dimensional Fund Advisors, Inc.0.64%
JPMorgan Chase & Co0.52%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Dr. Reddy’s Laboratories Ltd ADR — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.